Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study
-
Published:2024-01-20
Issue:
Volume:
Page:
-
ISSN:0167-6806
-
Container-title:Breast Cancer Research and Treatment
-
language:en
-
Short-container-title:Breast Cancer Res Treat
Author:
Coombes Charles, Angelou Christina, Al-Khalili Zamzam, Hart William, Francescatti Darius, Wright Nicholas, Ellis Ian, Green Andrew, Rakha Emad, Shousha Sami, Amrania HemmelORCID, Phillips Chris C., Palmieri Carlo
Abstract
Abstract
Purpose
Digistain Index (DI), measured using an inexpensive mid-infrared spectrometer, reflects the level of aneuploidy in unstained tissue sections and correlates with tumor grade. We investigated whether incorporating DI with other clinicopathological variables could predict outcomes in patients with early breast cancer.
Methods
DI was calculated in 801 patients with hormone receptor-positive, HER2-negative primary breast cancer and ≤ 3 positive lymph nodes. All patients were treated with systemic endocrine therapy and no chemotherapy. Multivariable proportional hazards modeling was used to incorporate DI with clinicopathological variables to generate the Digistain Prognostic Score (DPS). DPS was assessed for prediction of 5- and 10-year outcomes (recurrence, recurrence-free survival [RFS] and overall survival [OS]) using receiver operating characteristics and Cox proportional hazards regression models. Kaplan–Meier analysis evaluated the ability of DPS to stratify risk.
Results
DPS was consistently highly accurate and had negative predictive values for all three outcomes, ranging from 0.96 to 0.99 at 5 years and 0.84 to 0.95 at 10 years. DPS demonstrated statistically significant prognostic ability with significant hazard ratios (95% CI) for low- versus high-risk classification for RFS, recurrence and OS (1.80 [CI 1.31–2.48], 1.83 [1.32–2.52] and 1.77 [1.28–2.43], respectively; all P < 0.001).
Conclusion
DPS showed high accuracy and predictive performance, was able to stratify patients into low or high-risk, and considering its cost and rapidity, has the potential to offer clinical utility.
Funder
National Institute for Health and Care Research
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference39 articles.
1. Gunda A, Eshwaraiah MS, Gangappa K, Kaur T, Bakre MM (2022) A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast. Breast Cancer Res Treat 196:299–310 2. Markopoulos C, Hyams DM, Gomez HL, Harries M, Nakamura S, Traina T, Katz A (2020) Multigene assays in early breast cancer: Insights from recent phase 3 studies. Eur J Surg Oncol 46:656–666 3. Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Pusztai L, Raab R, Wolff AC, Stearns V (2022) Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 40:1816–1837 4. Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, Raphael J, Brackstone M (2020) Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. Pharmacogenomics J 20:27–46 5. Assi HI, Alameh IA, Khoury J, Abdul Halim N, El Karak F, Farhat F, Berro J, Sbaity E, Charafeddine M, Tfayli A, Salem Z, El Saghir N (2020) Impact of commercialized genomic tests on adjuvant treatment decisions in early stage breast cancer patients. J Oncol 2020:9238084
|
|